ASMB icon

Assembly Biosciences

10.49 USD
+0.08
0.77%
Updated Apr 24, 10:05 AM EDT
1 day
0.77%
5 days
5.43%
1 month
-5.67%
3 months
-28.98%
6 months
-38.04%
Year to date
-38.83%
1 year
-22.18%
5 years
-95.20%
10 years
-94.35%
 

About: Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Employees: 73

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

223% more capital invested

Capital invested by funds: $15.5M [Q3] → $50.3M (+$34.7M) [Q4]

100% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 5

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

33.92% more ownership

Funds ownership: 16.17% [Q3] → 50.09% (+33.92%) [Q4]

17% more funds holding

Funds holding: 30 [Q3] → 35 (+5) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$31
196%
upside
Avg. target
$31
196%
upside
High target
$31
196%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Guggenheim
Vamil Divan
31% 1-year accuracy
9 / 29 met price target
196%upside
$31
Buy
Initiated
25 Mar 2025

Financial journalist opinion

Based on 3 articles about ASMB published over the past 30 days

Neutral
GlobeNewsWire
2 weeks ago
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations –
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
Positive
Zacks Investment Research
2 weeks ago
Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround
Positive
Zacks Investment Research
4 weeks ago
Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock?
Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock?
Neutral
GlobeNewsWire
1 month ago
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline –
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
Neutral
GlobeNewsWire
1 month ago
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will be assessed in addition to safety and pharmacokinetic measures – SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1a trial of ABI-6250, the company's orally bioavailable, small molecule hepatitis delta virus (HDV) entry inhibitor candidate.
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
Neutral
GlobeNewsWire
2 months ago
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
– ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose –
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
Neutral
GlobeNewsWire
3 months ago
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B
– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed –
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B
Positive
Zacks Investment Research
7 months ago
Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year?
Here is how Assembly Biosciences (ASMB) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year?
Neutral
GlobeNewsWire
9 months ago
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented –
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
Neutral
GlobeNewsWire
10 months ago
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 –
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
Charts implemented using Lightweight Charts™